Acylglycerol Kinase (AGK) suppression sensitizes glioblastoma to Temozolomide by amplifying mitochondrial damage-related senescence
Background
Despite being the first-line treatment for glioblastoma (GBM), Temozolomide (TMZ) often faces tumor cell resistance, limiting patient survival. A key factor in this resistance is cellular senescence (CSEN), which can paradoxically promote tumor progression and is closely linked to mitochondrial dysfunction. Acylglycerol kinase (AGK), a mitochondrial membrane kinase, is known to regulate mitochondrial function and reactive oxygen species (ROS) production, making it a potential target to overcome TMZ resistance by modulating CSEN.
Study Design
Researchers investigated AGK's role in GBM progression and TMZ resistance using both clinical data and cell experiments. They analyzed TCGA data to correlate AGK expression with patient prognosis. In vitro, they used AGK-knockdown and AGK-overexpression in GBM cell lines to assess proliferation and TMZ resistance. They then explored the mechanism by measuring mitochondrial ROS (mtROS) and membrane potential. Finally, they tested the therapeutic potential of the mtROS scavenger Mito-TEMPO and the senolytic agent FOXO4-DRI in combination with TMZ to eliminate senescent cells and enhance TMZ efficacy.
Results
Analysis of TCGA data revealed that increased AGK expression correlated with a poor prognosis in GBM patients. In cell experiments, AGK suppression inhibited tumor cell proliferation. However, paradoxically, AGK suppression also promoted TMZ resistance. Mechanistically, this resistance was linked to AGK suppression amplifying TMZ-induced cellular senescence (CSEN). This amplification occurred through a significant increase in mitochondrial ROS (mtROS) and a decrease in mitochondrial membrane potential. Importantly, interventions targeting these pathways reversed the resistance:
Both Mito-TEMPO, a
mtROSscavenger, and FOXO4-DRI, a senolytic agent, enhanced the therapeutic efficacy of TMZ by eliminating these senescent cells via apoptosis. Further clinical analysis corroborated these findings, linking AGK levels, CSEN, and the prognosis of GBM patients treated with TMZ, establishing senescence induction as a novel mechanism for AGK-mediated TMZ sensitization.
Key Findings
- Increased AGK expression correlated with poor prognosis in glioblastoma patients.
- AGK suppression inhibited tumor cell proliferation but paradoxically promoted TMZ resistance.
- AGK suppression amplified TMZ-induced cellular senescence by increasing mitochondrial ROS and decreasing membrane potential.
- Mito-TEMPO (mtROS scavenger) enhanced TMZ efficacy by eliminating senescent cells.
- FOXO4-DRI (senolytic agent) enhanced TMZ efficacy by eliminating senescent cells via apoptosis.
Why It Matters
This research identifies AGK as a critical modulator of TMZ sensitivity in glioblastoma, suggesting a novel therapeutic strategy. For clinicians and researchers, co-targeting AGK and cellular senescence represents a promising approach to overcome TMZ resistance, a major hurdle in GBM treatment. While still in preclinical stages, the findings highlight the potential for combining traditional chemotherapy with senolytic agents or mtROS scavengers to improve patient outcomes. This could lead to enhanced TMZ efficacy and better survival rates for GBM patients by addressing therapy-induced senescence. Further research is needed to translate these in vitro findings into human clinical protocols.
glioblastoma
temozolomide
acylglycerol-kinase
cellular-senescence
mitochondrial-dysfunction
mtros